Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $2,482,409.56 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 91,198 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the transaction, the insider owned 765,188 shares of the company’s stock, valued at approximately $20,828,417.36. This trade represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN traded down $0.97 during mid-day trading on Monday, reaching $25.03. 1,373,161 shares of the company’s stock were exchanged, compared to its average volume of 2,697,186. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $29.98. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -13.60 and a beta of 0.41. The business’s fifty day moving average price is $19.07 and its 200-day moving average price is $19.95.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several analyst reports. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after purchasing an additional 1,693 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares during the period. Jane Street Group LLC acquired a new position in Enliven Therapeutics during the 1st quarter worth approximately $578,000. Rhumbline Advisers boosted its holdings in Enliven Therapeutics by 4.9% in the first quarter. Rhumbline Advisers now owns 52,502 shares of the company’s stock worth $1,033,000 after acquiring an additional 2,466 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its stake in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after acquiring an additional 2,500 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.